Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bottrop – page 112

1 691 clinical trials in Bottrop, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bottrop at a glance
1 691
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 691 trials in Bottrop

Open in trial search

Study of Emrusolmin for Treating Adults with Multiple System Atrophy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Emrusolmin
  • Sponsor:Teva Branded Pharmaceutical Products R&D LLC

Colon cancer stage II+1

Not recruiting

Study on Adjuvant Therapy with Capecitabine for Stage II Colon and Rectal Cancer Patients with Positive ctDNA After Tumor Removal

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Technische Universitat Dresden

Study on Gene Therapy with VTX-801 and Copper (64Cu) Chloride for Adults with Wilson's Disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Copper (64CU) chloride
  • Sponsor:Vivet Therapeutics

Study of Durvalumab, Tremelimumab, and Lenvatinib with TACE for Patients with Liver Cancer (Hepatocellular Carcinoma)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Study on Tafasitamab and Lenalidomide with Standard Therapy for Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma Patients

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Incyte Corp.

Long-Term Study of BI 1015550 for Patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nerandomilast
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study Comparing Sacituzumab Govitecan with Standard Treatment for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Study of [177Lu]Lu-NeoB and Capecitabine for Patients with Advanced Breast Cancer Resistant to Hormone Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Novartis Pharma AG

Multiple sclerosis+1

Not recruiting

Study on B-Cell Levels in Infants Exposed to Ocrelizumab During Pregnancy for Mothers with Multiple Sclerosis or Clinically Isolated Syndrome

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

Arteriosclerosis+1

Not recruiting

Study on Reducing Lipoprotein Apheresis with Pelacarsen in Patients with High Lipoprotein(a) and Heart Disease in Germany

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen
  • Sponsor:Novartis Pharma AG

Study on Acalabrutinib for Very Old or Frail Patients with Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:University Of Cologne

Study of nivolumab, relatlimab and bevacizumab combination for patients with untreated advanced or metastatic liver cancer (hepatocellular carcinoma)

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Bristol Myers Squibb International Corporation

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bottrop

What the registry says about research in the country

01 Breast Cancer Research

Extensive clinical trials focusing on hormone receptor-positive (HR+) and HER2-negative breast cancer treatments, evaluating innovative therapeutic approaches.

  • Early-stage breast cancer treatments
  • Metastatic disease management
  • Targeted therapy combinations

Studies include evaluation of novel drugs like ribociclib, elacestrant, and olaparib in combination with endocrine therapy.

02 Triple Negative Breast Cancer

Research investigating immunotherapy combinations and novel treatment approaches for patients with triple-negative breast cancer.

  • Post-surgery treatment optimization
  • Combination therapy assessment
  • Survival outcome improvements

Clinical trials evaluating sacituzumab govitecan-hziy with pembrolizumab versus standard treatments.

03 Ovarian Cancer Studies

Investigations into treatment strategies for advanced ovarian cancer, including peritoneal and fallopian tube cancers.

  • First-line therapy optimization
  • Combined treatment approaches
  • Progressive disease management

Focus on evaluating niraparib and bevacizumab combinations following chemotherapy.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.